The Elekta Esteya Electronic Brachytherapy System in Non-melanoma Skin Cancers: A Post-market Observational Study

Overview

Journal J Contemp Brachytherapy

Date 2025 Feb 13

PMID 39943976

Authors

Jonathan Cheng

Gerrit V Henry

Maureen R Lyden

Daniel I Shrager

Michael H Swann

James B Stubbs

Robert J Willard

Edward K Lee

Affiliations

Soon will be listed here.

Abstract

Purpose: The study was conducted to provide support for the delivery of electronic brachytherapy (EBx) in patients with low-risk non-melanoma skin cancer (NMSC) lesions who prefer and benefit a non-surgical treatment.

Material And Methods: This study included 205 patients with a total of 236 lesions. Six centers participated in this study using high-dose-rate EBx in NMSC. Eligible patients had pathologically confirmed basal cell or squamous cell carcinoma of clinical stage Tis, T1, or T2, with two or fewer high-risk clinical or pathologic features. Treatment doses were chosen from a set of fractionation schemes delivering 69-72 Gy (BED). Maximum follow-up was 5 years.

Results: The median age was 74 (range, 56-96) years, and 62% of the subjects were males and 38% females. The median follow-up was 24.2 months, with a maximum of 73.5 months. Healthcare professional (HCP) and patient-rated cosmesis were rated excellent/good (E/G) by both groups at 90-100% rates, except for HCP ratings of 1-3 months post-EBx, where cosmesis was rated 83-87% E/G. Erythema was the most common acute adverse event (34.1% at 1 month), rebounding back to zero by 6 months. There was a single lesion recurrence.

Conclusions: This report provides additional phase IV clinical data on NMSC treated with electronic brachytherapy. With 2-year median follow-up, there was one recurrence (0.42%). Patients tolerated the treatments well, as evidenced by strong and longitudinal scores on the skin cancer index as well as cosmetic evaluations performed by both patients and healthcare providers. Adverse rates were low, except for expected acute erythema, chronic hypopigmentation, and telangiectasia. The study provides additional information on EBx delivery for low-risk NMSC lesions in patents who prefer non-surgical treatment, especially those at risk for surgical complications, surgical cosmesis issues, keloid formation, wound care issues, and use of anticoagulant therapy.

References

Tormo A, Celada F, Rodriguez S, Botella R, Ballesta A, Kasper M . Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes. J Contemp Brachytherapy. 2014; 6(2):167-72. PMC: 4105643. DOI: 10.5114/jcb.2014.43247. View

Pons-Llanas O, Ballester-Sanchez R, Celada-Alvarez F, Candela-Juan C, Garcia-Martinez T, Llavador-Ros M . Clinical implementation of a new electronic brachytherapy system for skin brachytherapy. J Contemp Brachytherapy. 2015; 6(4):417-23. PMC: 4300364. DOI: 10.5114/jcb.2014.47996. View

Welsch M, Troiani B, Hale L, DelTondo J, Helm K, Clarke L . Basal cell carcinoma characteristics as predictors of depth of invasion. J Am Acad Dermatol. 2012; 67(1):47-53. DOI: 10.1016/j.jaad.2011.02.035. View

Nestor M, Berman B, Goldberg D, Cognetta Jr A, Gold M, Roth W . Consensus Guidelines on the Use of Superficial Radiation Therapy for Treating Nonmelanoma Skin Cancers and Keloids. J Clin Aesthet Dermatol. 2019; 12(2):12-18. PMC: 6415702. View

Rogers H, Weinstock M, Feldman S, Coldiron B . Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol. 2015; 151(10):1081-6. DOI: 10.1001/jamadermatol.2015.1187. View

Nguyen T . Nonmelanoma skin cancer. Curr Treat Options Oncol. 2002; 3(3):193-203. DOI: 10.1007/s11864-002-0009-0. View

Ashby M, Smith J, Ainslie J, McEwan L . Treatment of nonmelanoma skin cancer at a large Australian center. Cancer. 1989; 63(9):1863-71. DOI: 10.1002/1097-0142(19900501)63:9<1863::aid-cncr2820630934>3.0.co;2-4. View

Shah C, Ouhib Z, Kamrava M, Koyfman S, Campbell S, Bhatnagar A . The American Brachytherapy society consensus statement for skin brachytherapy. Brachytherapy. 2020; 19(4):415-426. DOI: 10.1016/j.brachy.2020.04.004. View

Cognetta Jr A, Wolfe C, Goldberg D, Hong H . Practice and Educational Gaps in Radiation Therapy in Dermatology. Dermatol Clin. 2016; 34(3):319-33. DOI: 10.1016/j.det.2016.02.011. View

10.

Martinez J, Otley C . The management of melanoma and nonmelanoma skin cancer: a review for the primary care physician. Mayo Clin Proc. 2002; 76(12):1253-65. DOI: 10.4065/76.12.1253. View

11.

Mosterd K, Krekels G, Nieman F, Ostertag J, Essers B, Dirksen C . Surgical excision versus Mohs' micrographic surgery for primary and recurrent basal-cell carcinoma of the face: a prospective randomised controlled trial with 5-years' follow-up. Lancet Oncol. 2008; 9(12):1149-56. DOI: 10.1016/S1470-2045(08)70260-2. View

12.

van Loo E, Mosterd K, Krekels G, Roozeboom M, Ostertag J, Dirksen C . Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014; 50(17):3011-20. DOI: 10.1016/j.ejca.2014.08.018. View

13.

Edge S, Compton C . The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471-4. DOI: 10.1245/s10434-010-0985-4. View

14.

Prager W, Pohlmann S, Kunze S . [The indications for and results of HDR afterloading therapy in diseases of the skin and mucosa with standardized surface applicators (the Leipzig applicator)]. Strahlenther Onkol. 1999; 175(4):170-4. View

15.

Gauden R, Pracy M, Avery A, Hodgetts I, Gauden S . HDR brachytherapy for superficial non-melanoma skin cancers. J Med Imaging Radiat Oncol. 2013; 57(2):212-7. DOI: 10.1111/j.1754-9485.2012.02466.x. View

16.

Donaldson M, Coldiron B . No end in sight: the skin cancer epidemic continues. Semin Cutan Med Surg. 2011; 30(1):3-5. DOI: 10.1016/j.sder.2011.01.002. View

17.

Richmond-Sinclair N, Pandeya N, Ware R, Neale R, Williams G, van der Pols J . Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population. J Invest Dermatol. 2008; 129(2):323-8. DOI: 10.1038/jid.2008.234. View

18.

Barysch M, Eggmann N, Beyeler M, Panizzon R, Seifert B, Dummer R . Long-term recurrence rate of large and difficult to treat cutaneous squamous cell carcinomas after superficial radiotherapy. Dermatology. 2012; 224(1):59-65. DOI: 10.1159/000337027. View

19.

Chan S, Dhadda A, Swindell R . Single fraction radiotherapy for small superficial carcinoma of the skin. Clin Oncol (R Coll Radiol). 2007; 19(4):256-9. DOI: 10.1016/j.clon.2007.02.004. View

20.

WOLF D, Zitelli J . Surgical margins for basal cell carcinoma. Arch Dermatol. 1987; 123(3):340-4. View